Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2007 1
2010 1
2011 1
2013 1
2018 1
2019 2
2021 1
2023 1
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study.
Girard N, Guisier F, Swalduz A, Van Hulst S, Pichon E, Lavaud P, Greillier L, Tiotiu A, Madroszyk A, Bylicki O, Canellas A, Belmont L, Zysman M, Hauss PA, Godbert B, Audigier-Valette C, Lebreton C, Morin F, Westeel V. Girard N, et al. Among authors: van hulst s. ESMO Open. 2024 Dec;9(12):103968. doi: 10.1016/j.esmoop.2024.103968. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608302 Free PMC article.
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
Spigel DR, Westeel V, Anderson IC, Greillier L, Guisier F, Bylicki O, Badin FB, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Le Treut J, Van Hulst S, Gandara DR, Reck M, Hoffknecht P, Gubens MA, Crowley J, von der Leyen H, Woodard GA, Jablons DM, Kratz JR, Mann MJ; AIM-HIGH investigators. Spigel DR, et al. Among authors: van hulst s. Lancet Respir Med. 2025 Oct;13(10):887-896. doi: 10.1016/S2213-2600(25)00213-9. Epub 2025 Jun 24. Lancet Respir Med. 2025. PMID: 40578381 Free article. Clinical Trial.
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study.
Filippi AR, García Campelo MR, Paoli JB, Kowalski D, Bennati C, Borghetti P, Cortinovis D, Delmonte A, Genova C, Van Hulst S, Mroz RM, Nawrocki S, Toledano I, Tonini G, Agustoni F, Wetherill G, Zhu Z, Perez ID, Foroutanpour K, Georgoulia N, Dziadziuszko R. Filippi AR, et al. Among authors: van hulst s. ESMO Open. 2025 Sep;10(9):105560. doi: 10.1016/j.esmoop.2025.105560. Epub 2025 Aug 20. ESMO Open. 2025. PMID: 40840233 Free article. Clinical Trial.
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.
Falchero L, Guisier F, Darrason M, Boyer A, Dayen C, Cousin S, Merle P, Lamy R, Madroszyk A, Otto J, Tomasini P, Assoun S, Canellas A, Gervais R, Hureaux J, Le Treut J, Leleu O, Naltet C, Tiercin M, Van Hulst S, Missy P, Morin F, Westeel V, Girard N. Falchero L, et al. Among authors: van hulst s. Lung Cancer. 2023 Nov;185:107379. doi: 10.1016/j.lungcan.2023.107379. Epub 2023 Sep 22. Lung Cancer. 2023. PMID: 37757576 Free article.
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Venat-Bouvet L, Cany L, Catala S, Khayat D, Gambotti L, Pauporté I, Faure-Mercier C, Paget-Bailly S, Henriques J, Grouin JM; PHARE trial investigators. Pivot X, et al. Lancet. 2019 Jun 29;393(10191):2591-2598. doi: 10.1016/S0140-6736(19)30653-1. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178155 Clinical Trial.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients.
Gounant V, Duruisseaux M, Soussi G, Van Hulst S, Bylicki O, Cadranel J, Wislez M, Trédaniel J, Spano JP, Helissey C, Chouaid C, Molinier O, Dhalluin X, Doucet L, Hureaux J, Cazes A, Zalcman G. Gounant V, et al. Among authors: van hulst s. Cancers (Basel). 2021 Mar 2;13(5):1040. doi: 10.3390/cancers13051040. Cancers (Basel). 2021. PMID: 33801285 Free PMC article.
12 results